Novel therapeutic molecular targets for prostate cancer: The mTOR signaling pathway and epidermal growth factor receptor

Anthony W. Tolcher, Ian M. Thompson, Leslie G. Ford, Neil Fleshner

Research output: Contribution to journalArticlepeer-review

29 Scopus citations

Abstract

Purpose: The scientific rationale and existing evidence for the use of novel molecular targets in the chemoprevention of cancer are reviewed, with special attention to prostate cancer. Materials and Methods: A search for relevant literature on basic science and clinical trials was conducted using PubMed/MEDLINE. Results: The emergence of molecularly targeted therapies for advanced malignancies creates an important opportunity to examine these agents for the chemoprevention of prostate cancer. Two critical targets in the proliferation and malignant transformation of normal cells, the PI3/Akt signal transduction pathway and the epidermal growth factor receptor, are currently the focus of several novel investigational therapies that are in late stage phase II and phase III studies. Conclusions: Research to date supports consideration of these novel molecular targets as future agents in the chemoprevention of prostate cancer.

Original languageEnglish (US)
Pages (from-to)S41-S44
JournalJournal of Urology
Volume171
Issue number2 II
DOIs
StatePublished - Feb 1 2004

Keywords

  • Prostatic neoplasms
  • Rapamycin
  • Receptor, epidermal factor

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Novel therapeutic molecular targets for prostate cancer: The mTOR signaling pathway and epidermal growth factor receptor'. Together they form a unique fingerprint.

Cite this